{"id":9195,"date":"2020-04-24T18:13:15","date_gmt":"2020-04-24T12:43:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9195"},"modified":"2024-09-18T15:04:28","modified_gmt":"2024-09-18T09:34:28","slug":"neoantigen-based-personalized-cancer-therapeutic-vaccines-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market","title":{"rendered":"Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines"},"content":{"rendered":"\n

Neoantigen based Personalized Cancer Therapeutic Vaccines Market is advancing owing to bioinformatics-technological advancements, improved diagnosis, and a strong pipeline. <\/strong><\/em><\/p><\/blockquote>\n\n\n\n

Cancer therapeutic vaccines, unlike prophylactic vaccines, form a therapeutic option for the late-stage cancer patients in which the body\u2019s immune cells target the cancerous cells. Therapeutic vaccines use weakened or inactive pathogens including virus, bacterium and others to create an immune response against the pathogens in the bod- directing the immune system to recognize, attack and destroy cancer cells. Neoantigen-based Personalized Cancer therapeutic Vaccines are one way to utilize the body\u2019s immune system to fight cancer.<\/p>\n\n\n\n

Neoantigens<\/strong><\/p>\n\n\n\n

Neoantigens are non-autologous proteins which are specific to\nindividuals and are a result of non-synonymous mutations in the tumor cell\ngenome. Their lack of expression in healthy tissues and strong immunogenicity\nhave always attracted the attention of scientist to be explored as the\npromising targets for cancer immunotherapies, including cancer vaccine as they activate\nCD4+ and CD8+ T cells. The feature of neoantigens to only express in tumor\ncells and not in healthy tissues is what gives then advantage over other\nantigens being explored for cancer immunotherapy. <\/p>\n\n\n\n

However; the development of such advanced therapies required\nadvanced technologies as well. A conflux of a wide range of\nbioinformatics-technological advancements such as next-generation DNA sequencing\ntechnology to scan and differentiate between tumor and healthy cells, identify\nmutations and discrepancies; sophisticated computer algorithms, and\nmanufacturing advances have made it feasible to leverage the use of neoantigens\nas cancer targets. <\/p>\n\n\n\n

Marketed Therapeutic Cancer\nVaccines <\/strong><\/p>\n\n\n\n

Several challenges remain while developing therapeutic cancer vaccines despite significant challenges that come across. However, the US FDA approval two Cancer therapeutic Vaccines, till date, proves to be encouraging as Cancer therapeutic vaccines market witnessed an influx of the pharma and biotech players and formation of several collaborations to advance the market. <\/p>\n\n\n\n

\"Neoantigen
Neoantigen based Personalized Cancer Therapeutic Vaccines Market <\/a><\/strong><\/figcaption><\/figure>\n\n\n\n

In the very first, BCG<\/strong> – the only human tuberculosis\n(TB) vaccine – was approved by the FDA in 1990 as a vaccine for early-stage\nbladder cancer, which later-on emerged as the most successful treatment of a non-muscle\ninvasive form of bladder cancer<\/a> (NMIBC). The vaccine reduces the risks of NMIBC\nrecurrence, and progression of NMIBC into muscle-invasive bladder cancer.\nDespite being the most promising immunotherapeutic agents, the therapy is\naccompanied by several setbacks and drawbacks in the form of treatment failure,\nside effects, and the short residence of the instilled BCG in the urothelial lumen\ndue to frequent bladder emptying. <\/p>\n\n\n\n

Nonetheless, recent advances in cancer immunology and\ninvigorating results from the trials have led the FDA to approve the use of\nDendreon\u2019s Provenge<\/strong> (Sipuleucel-T) for prostate cancer in 2010 as the\nfirst therapeutic cancer vaccine. The vaccine is autologous cellular\nimmunotherapy indicated for the treatment of asymptomatic or minimally\nsymptomatic metastatic\ncastrate-resistant (hormone-refractory) prostate cancer<\/a>. <\/p>\n\n\n\n

However, it is not a Neoantigen based Cancer Vaccines; and it\nis not to be skipped that till date,\nno neo-antigen based personalized vaccine has received any regulatory approval.\n<\/p>\n\n\n\n

Neoantigen<\/strong> based Personalized Cancer Therapeutic Vaccines<\/strong> Market:<\/strong> In the Pipeline <\/strong><\/p>\n\n\n\n

Neoantigen-based cancer vaccines\nhave recently showed marked therapeutic potential in both preclinical and\nearly-phase as well as late-phase clinical studies. <\/p>\n\n\n\n

A spectrum of therapeutic vaccination and strategies to cope\nup with the increasing cancer burden are under development or being evaluated\nin clinical trials. Classified based on cell vaccines (tumor or immune cell),\nprotein\/peptide vaccines, and genetic (DNA, RNA and viral) vaccines, several Neoantigen-based\nPersonalized Cancer therapeutic Vaccines are expected to enter the market by\n2035 that shall increase the market size.<\/p>\n\n\n\n

The emerging products in the Neoantigen-based\nPersonalized Cancer therapeutic Vaccines market<\/a><\/strong> appear to be quite\npromising with different vaccines in different stages of clinical development.<\/p>\n\n\n\n

Several key players such as Gradalis<\/strong>, OSE\nImmunotherapeutics<\/strong>, Immunitor<\/strong>, Gritstone<\/strong> Oncology<\/strong>, Genocea<\/strong>,\nTargovax<\/strong>, Hangzhou<\/strong> Neoantigen<\/strong> Therapeutics<\/strong>, Neon<\/strong>\nTherapeutics<\/strong> along with many others are robustly involved in fuelling Neoantigen-based\nPersonalized Cancer therapeutic Vaccines market. Neoantigen-based Personalized\nCancer therapeutic Vaccines that are in the pipeline comprise of potential and\npromising products including Vigil<\/strong> (Gradalis), Tedopi<\/strong> (OSE Immunotherapeutics),\nHepko-V5<\/strong> (Immunitor), GRANITE<\/strong> (GRT-C901) + SLATE<\/strong>\n(GRT-R902) (Gritstone Oncology), GEN-009<\/strong> (Genocea), TG01<\/strong> Vaccine<\/strong>\n(Targovax), iNeo-Vac-P01<\/strong> (Hangzhou Neoantigen Therapeutics), NEO-PV-01<\/strong>\n(Neon Therapeutics) and many others.<\/p>\n\n\n\n

Neoantigen based Personalized Cancer therapeutic Vaccines Market Segmentation <\/strong><\/p>\n\n\n\n

Neoantigen-based Personalized Cancer therapeutic Vaccines are\nunder evaluation for several types of cancers including Lung cancers, Bone\nCancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Urothelial\nCarcinoma, Cutaneous Melanoma, Renal Cell Carcinoma and others, each with their\nrespective sub-types.<\/p>\n\n\n\n

In terms of indications, the most substantial chunk of Neoantigen-based\nPersonalized Cancer therapeutic Vaccines Market share shall be occupied by the Non-small\ncell lung cancer (NSCLC)<\/a> with various Neoantigen based cancer vaccines in\nthe pipeline for the indication in the 7MM expected to be launched by 2035.  <\/p>\n\n\n\n

DelveInsight estimates that NSCLC<\/a>\nshall account for 36.7% of <\/strong>Neoantigen-based personalized cancer therapeutic\nvaccines market share by 2035 in the United States in the 7MM. In addition to\nNSCLC, Melanoma, and Bladder cancer shall also account for significant Neoantigen-based\npersonalized cancer therapeutic vaccines market share with Brain and Bone\ncancer<\/a> anticipated to occupy the lowest share. <\/p>\n\n\n\n

Moreover, the cancer indications that will witness significant\nadvancements during the forecast period concerning a good number of upcoming\nvaccines are Ewing Sarcoma, Ovarian Cancer, melanoma \u2013 with Gradalis working to\nadvance the market, NSCLC market fuelled by OSE Immunotherapeutics, and Hepatocellular\nCarcinoma therapy market advanced by Immunitor along with others.<\/p>\n\n\n\n

Market drivers <\/strong><\/p>\n\n\n\n

Owing to the launch of upcoming therapies, ongoing research\nand development, and a shift towards personalized treatment approach neoantigen-based\npersonalized cancer therapeutic vaccines market size shall increase during the\nforecast period by 2035 in the 7MM. <\/p>\n\n\n\n

Additionally, assisted by an increase in the diagnosed\nincident population of several cancer indications and the advancements in\ntreatment options makes it irrefutable that upcoming cancer vaccine is majorly expected\nto boom the overall therapeutic market in the oncology sector by acting as an\nadjuvant therapy to the already existing Standard of care therapies (SOC). <\/p>\n\n\n\n

Thus, therapeutic\ncancer vaccines \u2013 especially, Neoantigen based \u2013 shows a bright future in cases\nwhere cancer recurs or relapses, which would not only provide hope in\nthe form of new treatment modality for cancer management but also pave the way\nfor optimizing vaccines. <\/p>\n","protected":false},"excerpt":{"rendered":"

Neoantigen based Personalized Cancer Therapeutic Vaccines Market is advancing owing to bioinformatics-technological advancements, improved diagnosis, and a strong pipeline. Cancer therapeutic vaccines, unlike prophylactic vaccines, form a therapeutic option for the late-stage cancer patients in which the body\u2019s immune cells target the cancerous cells. Therapeutic vaccines use weakened or inactive pathogens including virus, bacterium and […]<\/p>\n","protected":false},"author":1,"featured_media":9200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[137,18255,18251,18254,18253,12404,18257,18252,17075],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-9195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-cancer","tag-genocea","tag-gradalis","tag-gritstone-oncology","tag-immunitor","tag-neoantigen","tag-neon-therapeutics","tag-ose-immunotherapeutics","tag-targovax","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nNeoantigen based Personalized Cancer Therapeutic Vaccines Market<\/title>\n<meta name=\"description\" content=\"Neoantigen based Personalized Cancer Therapeutic Vaccines Market size shall increase by 2035 in 7MM owing to a strong pipeline, improved cancer diagnosis...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neoantigen based Personalized Cancer Therapeutic Vaccines Market\" \/>\n<meta property=\"og:description\" content=\"Neoantigen based Personalized Cancer Therapeutic Vaccines Market size shall increase by 2035 in 7MM owing to a strong pipeline, improved cancer diagnosis...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-24T12:43:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:34:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market","description":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market size shall increase by 2035 in 7MM owing to a strong pipeline, improved cancer diagnosis...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market","og_locale":"en_US","og_type":"article","og_title":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market","og_description":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market size shall increase by 2035 in 7MM owing to a strong pipeline, improved cancer diagnosis...","og_url":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-24T12:43:15+00:00","article_modified_time":"2024-09-18T09:34:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market","url":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market","name":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer.jpg","datePublished":"2020-04-24T12:43:15+00:00","dateModified":"2024-09-18T09:34:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market size shall increase by 2035 in 7MM owing to a strong pipeline, improved cancer diagnosis...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/neoantigen-based-personalized-cancer-therapeutic-vaccines-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer.jpg","width":772,"height":482,"caption":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/24180653\/Changing-Paradigm-of-Cancer-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Genocea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gradalis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gritstone Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immunitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neoantigen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neon Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">OSE Immunotherapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Targovax<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Genocea<\/span>","<span class=\"advgb-post-tax-term\">Gradalis<\/span>","<span class=\"advgb-post-tax-term\">Gritstone Oncology<\/span>","<span class=\"advgb-post-tax-term\">Immunitor<\/span>","<span class=\"advgb-post-tax-term\">Neoantigen<\/span>","<span class=\"advgb-post-tax-term\">Neon Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">OSE Immunotherapeutics<\/span>","<span class=\"advgb-post-tax-term\">Targovax<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 24, 2020","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Apr 24, 2020 6:13 pm","modified":"Updated on Sep 18, 2024 3:04 pm"},"featured_img_caption":"Neoantigen based Personalized Cancer Therapeutic Vaccines Market ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9195"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9195\/revisions"}],"predecessor-version":[{"id":29615,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9195\/revisions\/29615"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9195"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9195"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}